

# <u>HealthTech For Care</u> and <u>EIT Health</u> publish the agenda of the 3<sup>rd</sup> edition of the <u>HealthTech Innovation Days</u> event next 4 & 5 October 2021

For this 3<sup>rd</sup> edition of the <u>HealthTech Innovation Days (HTID®)</u>, placed under the High Patronage of Mr Emmanuel Macron, President of the French Republic, the European healthcare ecosystem will gather around tomorrow's health major challenges: Artificial Intelligence, health data regulation, impact of the Covid-19 crisis and antibiotic resistance or robotics. The HTID mobilises both international sponsors and European clusters.

**Paris, France, 5 July 2021** - The event aims at widely sharing current thinking and actions with leaders in health innovation, global pharmaceutical companies, investors, political representatives and patient organisations. This event, which will again take place in a hybrid format, will also bring together several hundred dedicated healthtech investors and will offer face-to-face and remote meetings between investors from all over the world, European healthtech companies and pharmaceutical groups, with the aim of creating partnerships to speed the time-to-market of innovations for patients.

Find out more about the main themes of the programme (link to the programme):

- **Policy & Financing issues:** what are the political and economic consequences of the Covid-19 crisis for the health sector in Europe?
- The technological challenges of tomorrow: what market access for solutions based on Artificial Intelligence and Robotics? <u>The European Parliament and Council reached a provisional agreement</u> on <u>Tuesday 22 June 2021 on health technology assessment (HTA)</u>, to help Member States make "faster evidence-based decisions on patient access" to their health systems.
- Major therapeutic challenges: the European Commission has unveiled its plan to fight cancer: 4 billion euros to fund prevention, research and treatment deployment programmes across the EU. By 2050, antibiotic resistance could kill more people than cancer. The World Bank also estimates that the financial impact of antibiotic resistance by 2050 would be comparable to that of the 2008 financial crisis.
- Accelerating innovation in health by providing cross-cutting solutions: the Covid crisis has highlighted the importance of innovation in the health sector. This applies both to clinical research (finding vaccines and treatments) and to the architecture of the healthcare system. In particular, cooperation between public and private players must be encouraged and innovation approaches centred on patient use must be integrated.
- How to attract, recruit and train the talents of tomorrow in the health sector? In order to adapt to new technologies and to the ageing of the population, healthcare professions are changing rapidly. While pharmaceutical laboratories and biotech companies were already facing a shortage of talents, the Covid-19 crisis triggered a highly targeted demand that revealed an over-reliance on foreign production.

The use of patient health data for innovation: sharing conclusions of <u>the HealthTech For Patients</u> event which brought together a panel of European actors and experts from the health ecosystem around the theme of health data for medical innovation. Indeed, health data are essentials to accelerate the development of innovative solutions for the patient and require global support from the ecosystem, both financial and industrial.

The 3<sup>rd</sup> edition of the HTID benefits from the support of sponsors among major global industrial groups such as <u>Amgen</u>, <u>Bristol-Myers Squibb</u>, <u>Microsoft</u>, <u>Sanofi</u>, <u>Servier</u>, influential players in healthtech, such as <u>Dechert</u>, <u>Financière Arbevel</u>, <u>Icosa</u>, <u>Invest Securities</u>, <u>Sofinnova Partners</u>, as well as institutional partners such as <u>Bpifrance</u>, <u>Euronext</u> and <u>Leem</u> (Les Entreprises du Médicament), which allow for the gathering of all the experts around the themes addressed.

# About HealthTech For Care

The HealthTech For Care Endowment Fund is designed to support and promote access to care for all and, in particular, new medical technologies and drugs. The missions of the endowment fund are organized around three main areas: supporting the development of the entire healthcare ecosystem, accelerating the development of innovative therapies and medicines, and promoting better access for patients to the healthcare system in France and Europe. HealthTech For Care is supported by its founder *France Biotech* and the network of French health cluster: *Atlanpole biotherapies, France BioValley, EuroBioMed, LyonBioPole, Medicen et le clubster NSL*. The endowment fund is also supported by many European players: *Asebio, Bio Deutschland, BioWin, CEBR, Federchimica Assobiotec, Flanders.bio, Irefi, LifeSci, P-Bio, SwendenBio and SwissBiotech*.

# About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and rowing multimorbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.

For more information visit: www.eithealth.eu

# About LifeSci Advisors

LifeSci Advisors are the global leading investor relations firm within Life Sciences. We combine deep domain life sciences expertise with decades of experience in capital markets to deliver services designed to increase our clients' visibility within the investment community across the U.S, Europe and Israel. For more information visit: <u>https://www.lifesciadvisors.com</u>

### About France Biotech, Founder of HealthTech For Care

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies' financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. <u>http://www.france-biotech.fr/</u>

### About HealthTech Innovation Days

The HTID event provides a platform for promising European life sciences companies to accelerate their growth and bring innovation to patients. The conference will take place on October 4&5 2021 on a hybrid format, combining inperson presentations, panels and one-on-one meetings in Paris with a virtual platform for those unable to travel. It is organized by HealthTech For Care and EIT Health, a network of best-in-class health innovators backed by the EU, to enable partnerships between healthcare companies as well as to secure funding from international, specialized healthcare investors. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, other corporates, investors, and many international thought leaders, as well as by by institutional partners such as <u>Emmanuel Macron</u>, President of the French Republic, <u>Thierry Breton</u>, Commissioner of the European Commission, <u>Agnès Pannier-Runacher</u>, Minister Delegate to the Minister of Economy, Finance and Recovery, in charge of Industry and <u>Alexandra Dublanche</u>, Vice-President of the Regional Council of Ile-De-France.

### **Contacts Presse**

Relations presse Najette Chaib <u>najettechaib@outlook.com</u> +33(0)6 18 38 11 14

EIT Health Jérôme Fabiano jerome.fabiano@eithealth.eu +33(0) 6 42 25 73 41 Sophie Baumont LifeSci Advisors sophie@lifesciadvisors.com +33(0)6 27 74 74 49

HTFC Nathalie Donne <u>nathalie.donne@insead.eu</u> +33(0)6 67 67 44 97

HTFC Solène Goupy <u>solene.goupy@htfc-eu.com</u> +33(0)6 38 03 80 19 France Biotech Florence Portejoie FP2COM fportejoie@fp2com.fr +33(0)6 07 76 82 83